ReviewAnais brasileiros de dermatologia
Bullous pemphigoid.
Review in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 4 syntheses or guidelines pooled it, 228 citations in OpenAlex.
- A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: therapeutic and paradoxical effects.Archives of dermatological research · 2025Pooled it
- Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis.Archives of dermatological research · 2023Pooled it
- Interventions for bullous pemphigoid.The Cochrane database of systematic reviews · 2023Pooled it
- Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.PloS one · 2022Pooled it
- KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid.International journal of dermatology · 2026Article
- Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.Skin health and disease · 2026Review
- Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study.The Journal of dermatology · 2026Observational
- Localized Bullous Pemphigoid Triggered by Surgical Trauma: A Case Highlighting the Koebner Phenomenon.Cureus · 2026Article
- Ramipril-Induced Annular Bullous Pemphigoid: A Clinical Mimic of Linear IgA Dermatosis.The Eurasian journal of medicine · 2026Article
- Bullous Hemorrhagic Dermatosis in a 65-year-old Filipino Woman Secondary to Enoxaparin: A Case Report.Acta medica Philippina · 2026Article
- Upadacitinib for the treatment of refractory bullous pemphigoid: a case report and literature review.Frontiers in immunology · 2026Review
- Multidisciplinary wound care in an elderly patient with extensive bullous pemphigoid: a case report.Frontiers in medicine · 2026Article
- Bullous pemphigoid exhibiting Koebner phenomenon.Annals of medicine and surgery (2012) · 2026Article
- Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.Postepy dermatologii i alergologii · 2026Article
- Corticosteroid-Sparing Control of Bullous Pemphigoid with Dupilumab and Tripterygium Glycosides: A Real-World Cohort with Longitudinal Transcriptomics.Journal of inflammation research · 2026Article
- Case Report: Simultaneous presence ofFrontiers in medicine · 2026Article
- Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: A case study.Human vaccines & immunotherapeutics · 2025Article
- An Unusual Case of Esophageal Bullous Pemphigoid at a Tertiary Care Center.Indian dermatology online journal · 2025Article
- Effectiveness and safety of methylprednisolone combination with abrocitinib compared to methylprednisolone combination with azathioprine in bullous pemphigoid: a retrospective study.Scientific reports · 2025Article
- Laryngeal Bullous Pemphigoid: A challenging presentation of a rare disease.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. Increase in incidence rates in the past decades has been attributed to population aging, drug-induced cases and improvement in the diagnosis of the nonbullous presentations of the disease. A dysregulated T cell immune response and synthesis of IgG and IgE autoantibodies against hemidesmosomal proteins (BP180 and BP230) lead to neutrophil chemotaxis and degradation of the basement membrane zone. Bullous pemphigoid classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense pruritus. Mucosal involvement is rarely reported. Diagnosis relies on (1) the histopathological evaluation demonstrating eosinophilic spongiosis or a subepidermal detachment with eosinophils; (2) the detection of IgG and/or C3 deposition at the basement membrane zone using direct or indirect immunofluorescence assays; and (3) quantification of circulating autoantibodies against BP180 and/or BP230 using ELISA. Bullous pemphigoid is often associated with multiple comorbidities in elderly individuals, especially neurological disorders and increased thrombotic risk, reaching a 1-year mortality rate of 23%. Treatment has to be tailored according to the patient's clinical conditions and disease severity. High potency topical steroids and systemic steroids are the current mainstay of therapy. Recent randomized controlled studies have demonstrated the benefit and safety of adjuvant treatment with doxycycline, dapsone and immunosuppressants aiming a reduction in the cumulative steroid dose and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.